Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2023-04-21 Environmental & Social …
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
深圳微芯生物科技股份有限公司2022年度社会责任报告
Environmental & Social Information Classification · 100% confidence The document is titled '2022年 社会责任报告' which translates to '2022 Social Responsibility Report'. It covers a wide range of topics including company strategy, governance, environmental management, employee welfare, R&D progress, and community engagement. The report spans the full year 2022 and is described as the company's second social responsibility report. It references ESG guidelines and standards, and includes detailed qualitative and quantitative data on social, environmental, and governance performance. There is no indication that this is a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an announcement or transcript. The content aligns with Environmental & Social Information (ESG) reporting. Therefore, the appropriate classification is Environmental & Social Information (SR).
2023-04-21 Chinese
关于2022年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's 2022 profit distribution plan, specifically stating that no profit distribution or capital reserve conversion to shares will be made. It includes details about the board and supervisory committee approvals, independent director opinions, and references to relevant laws and regulations. The document is relatively short (1903 characters) and serves as a formal announcement of a corporate decision related to dividends rather than the dividend notice itself or a full financial report. It does not contain actual financial statements or detailed financial data but rather the decision and rationale behind the profit distribution plan. Therefore, it fits best under the category of Notice of Dividend Amount (DIV), as it announces the dividend decision and related information to shareholders.
2023-04-21 Chinese
深圳微芯生物科技股份有限公司2022年度报告摘要
Annual Report Classification · 98% confidence The document is titled as "2022 年度报告摘要" which translates to "2022 Annual Report Summary". It contains detailed financial data for the year 2022, including profit, revenue, net assets, and quarterly breakdowns. It also includes extensive business descriptions, risk disclosures, shareholder information, and operational details. The document is over 13,000 characters, indicating it is a substantive report rather than a brief announcement. The presence of comprehensive financial and operational data, management discussion, and risk factors aligns with the characteristics of an Annual Report (10-K). There is no indication that this is merely an announcement or a certification, nor is it a quarterly or interim report. Therefore, the document is best classified as an Annual Report (10-K). FY 2022
2023-04-21 Chinese
独立董事关于公司续聘会计师事务所的事前认可意见
Audit Report / Information Classification · 90% confidence The document is a statement from independent directors regarding the prior approval of the company's proposal to reappoint the auditing firm for the 2023 fiscal year. It references the company's board meeting agenda and the auditing firm's past performance. The document is short (673 characters) and does not contain any financial statements or detailed audit results. It is essentially an approval opinion related to the appointment of the auditor, not the audit report itself. Therefore, it fits best under Audit Report / Information (AR), which includes standalone audit reports and related audit information such as auditor appointments and approvals. FY 2023
2023-04-21 Chinese
关于2022年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's fundraising activities, specifically focusing on the storage and actual use of raised funds during the fiscal year 2022. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and includes detailed tables of fundraising amounts, usage, balances, and investment projects. It also includes auditor and sponsor opinions on the fundraising usage. The document is titled as a "专项报告" (special report) on the storage and use of raised funds for the year 2022. This type of document corresponds to a specialized report on capital raising and usage, which aligns with the category "Capital/Financing Update (CAP)". It is not a full annual report, audit report, or earnings release, but a focused report on fundraising and capital usage. The document length is substantial and contains detailed financial data related to fundraising and capital management, confirming it is a substantive report rather than a mere announcement or certification.
2023-04-21 Chinese
深圳微芯生物科技股份有限公司2022年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as the "2022年度独立董事述职报告" which translates to "2022 Annual Independent Directors' Report". It details the independent directors' duties, attendance at meetings, review of company operations, compliance with laws and regulations, and other governance-related activities for the year 2022. The content focuses on the independent directors' performance and governance oversight rather than financial results or audit opinions. It is not an annual report (10-K), audit report (AR), or earnings release (ER). It is a detailed report related to board/management activities and governance. Given the focus on independent directors' duties and governance, the most appropriate classification is Board/Management Information (MANG). The document length is over 5,000 characters and contains substantive content, so it is not a mere announcement or certification. Therefore, the classification is MANG with high confidence.
2023-04-21 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.